Hemophilia A can be hereditary or, rarely, acquired later in life. Treatment for hemophilia A continues to evolve. Preventive treatment (prophylaxis) has relied on factor VIII products given through ...

The gene therapy biotech was later acquired by Roche, which has had its own struggles with the modality in hemophilia. With its Sangamo partnership terminated and Beqvez being discontinued ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...

In December 2014, five years before Spark was acquired by Swiss drug giant Roche ... payment from Pfizer in 2015 when the experimental hemophilia B gene therapy entered Phase 1 clinical testing.

Pfizer had acquired the asset in the Bamboo acquisition ... linked to the development of a gene therapy candidate targeting hemophilia A. This decision came months after Pfizer announced positive ...

Morgan Stanley reaffirmed their overweight rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report report published on Friday,Benzinga reports. The firm currently ...

Hemophilia growth was 11% ... Our Phase 3 study evaluating RiaSTAP for the treatment of acquired fibrinogen deficiency is progressing in Europe and we are preparing for a filing in the US.

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Newly acquired product Nurtec ODT/Vydura contributed ... Pfizer terminated its global collaboration with Sangamo for the hemophilia A candidate, giroctocogene fitelparvovec. It will return rights ...